Metabolic therapy of heart failure

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2582-2591

  Fragasso, Gabriele ^a   Salerno, Anna ^a   Spoladore, Roberto ^a   Bassanelli, Giorgio ^a   Arioli, Francesco ^a   Margonato, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Carnitine palmitoyl transferase I (CPT I); Free fatty acids inhibitors; Heart failure; Left ventricular function; Metabolic therapy; Myocardial metabolism; Trimetazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE INHIBITOR; ADENOSINE TRIPHOSPHATE; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CARNITINE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CREATINE KINASE; CREATINE PHOSPHATE; DOBUTAMINE; ENDOTHELIN; ETOMOXIR; FATTY ACID INHIBITOR; METFORMIN; PERHEXILINE; PLACEBO; RANOLAZINE; TRIMETAZIDINE; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANGINA PECTORIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEPLETION; QT PROLONGATION; REVIEW;

ANIMALS; CARDIOVASCULAR AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; FATTY ACIDS, NONESTERIFIED; HEART FAILURE; HUMANS; MYOCARDIUM; PERHEXILINE; TRIMETAZIDINE;

EID: 57349127248     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071245     Document Type: Review

References (110)

1. Suga H. Ventricular energetics. Physiol Rev 1990; 70: 247-77.
2. Mc Veigh JJ, Lopaschuck GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990; 259: H1070-85.
3. Nicholl TA, Lopaschuck GD, McNeill GH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat hearts: Am J Physiol 1991; 261: H1053-9.
4. Bersin RM, Wolfe C, Kwasman M, Laud D, Klinski C, Tanaka K, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-24.
5. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58.
6. Kantor PF, Lucien A, Kozak R, Lopashuck GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
7. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e26-32.
8. MacInness A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, et al. The antianginal trimetazidine does not exert its functional benefit via inhibition of mithocondrial longchain 3- ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e33-7.
9. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-10.
10. Lopaschuck GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997; 95: 313-5.
11. Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulkki K, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996; 28: 665-72.
12. Riley M, Bell N, Elborn JS, Stanford CF, Buchanan KD, Nicholls DP. Metabolic response to graded exercise in chronic heart failure: Eur Heart J 1993; 14: 1484-8.
13. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 1991; 40: 972-7.
14. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teras M, Voipio-Pulkki LM, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 1994; 267: E941-6.
15. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
16. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-34.
17. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
18. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
19. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
20. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003; 146: E1-8.
21. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16/1-16/9.
22. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
23. Di Napoli P, A A Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
24. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol 2007; 62: 493-9.
25. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585-9.
26. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
27. 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-6.
28. 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23.
29. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, et al. The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94: 1894-901.
30. Fragasso G, De Cobelli F, Perseghin G, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
31. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
32. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
33. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8: 416-22.
34. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, et al. Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure. Circ Res 2002; 91: 278-80
35. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 5: 741-7.
36. Aaker A, McCormack JG, Hirai T, Musch TI. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 353-62.
37. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-8.
38. Opie LH. The metabolic vicious circle in heart failure. Lancet 2004; 364: 1733-4.
39. Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M, et al. Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-52.
40. Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S, et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes J Clin Endocrinol Metab 2000; 85: 2416-20.
41. Crettaz M, Zaninetti D, Jeanrenaud B. Insulin-resistance in heart and skeletal muscles of genetically obese Zucker rats. Biochem Soc Trans 1981; 9: 524-5.
42. Natali A, Taddei S, Quiñones Galvan A, Camastra S, Baldi S, Frascerra S, et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation 1997; 96: 725-6.
43. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
44. Piatti P, Fragasso G, Monti LD, Caumo A, Van Phan C, Valsecchi G, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1999; 34: 1452-60
45. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, et al. Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation 2003; 108: 2074-81.
46. The Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21
47. Cano C, Bermúdez VJ, Medina MT, Bermúdez FA, Ambard MJ, Souki AJ, et al. Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: a preliminary study. Am J Ther 2003; 10: 444-6.
48. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, et al. Metabolic and Endothelial Effects of Trimetazidine on Forearm Muscle in Patients with Type 2 Diabetes and Ischemic Cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-9.
49. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309-16.
50. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27: 42-8.
51. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007: 297: 1775-83.
52. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-10.
53. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007; 99: 113B-32B.
54. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-51.
55. Inzucchi SE. Metformin and heart failure: innocent until proven guilty. Diabetes Care 2005; 28: 2585-7.
56. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51: 93-102
57. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-601.
58. Parodi O, De Maria R, Roubina E. Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate-thiol interaction. J Cardiovasc Med (Hagerstown) 2007; 8: 765-74.
59. Traverse JH, Chen Y, Hou M, Bache RJ. Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 282: H2278-83.
60. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-6.
61. Fragasso G, Piatti P, Monti L, Palloshi A, Lu C, Valsecchi G, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002; 39: 413-9.
62. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin production in the heart and beneficial effect of endothelin A antagonist on survival and cardiac function. Circulation 1999; 99: 2171-6.
63. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-51.
64. Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J, et al. Chronic L-arginine supplementation enhances endurance exercise tolerance in heart failure patients. Int J Sports Med 2006; 277: 567-72.
65. Wallhaus TR, Taylor M, DeGrado TR, Russell DC. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-6.
66. Podbregar M, Voga G. Effect of selective and nonselective betablockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Cardiav Fail 2002: 8: 369-78.
67. Sharma V, Dhillon P, Wambolt RB, Parsons HL, Brownsey R, Allard MF, et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin (STZ) diabetic rat. Am J Physiol Heart Circ Physiol 2008; 294: H1609-20.
68. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol (Or Metoprolol European Trial (COMET) randomised controlled trial. Lancet 2003; 362: 7-13.
69. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-67.
70. Mobini R, Jansson PA, Bergh CH, Sharing Tang M, Waagstein F, Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci 2006; 110: 329-36.
71. Lopashuck GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63:1036-43.
72. Ratheiser K, Schneeweiss B, Waldhäusl W, Fasching P, Korn A, Nowotny P, et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991; 40: 1185-90.
73. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997; 96: 3681-6.
74. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002;11: 345-56.
75. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000; 99: 27-35.
76. Schmitz FJ, Rösen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 1995; 27: 515-22.
77. Cabreros A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003; 44: 388-98.
78. Merrill CL, Ni H, Yoon LW, Tirmenstein MA, Narayanan P, Benavides GR, et al. Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002; 68: 93-101.
79. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007; 113: 205-12.
80. Kennedy JA, Kiosoglus AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexilline and oxfenicine on myocardial function and metabolism during low flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36: 794-801
81. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Mallory CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25: 469-72.
82. Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985; 227: 651-60.
83. Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1980; 1: 247-53.
84. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
85. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of shortterm use of a novel treatment. Circulation 2005; 112: 3280-8.
86. Meier C, Wahllaender A, Hess CW, Preisig R. Perhexiline-induced lipidosis in the dark Agouti (DA) rat: an animal model of genetically determined neurotoxicity. Brain 1986; 109: 649-60.
87. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1: 193-204.
88. Broderick BL, Quinney HA, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993: 87: 972-81.
89. Cevese A, Schena F, Cerotti G. Short-term hemodynamic effects of intravenous propionyl-l-carnitine in anesthetized dogs. Cardiologia 1989; 34: 95-101.
90. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91.
91. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2 in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536-9.
92. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-6.
93. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998; 352(suppl 1): SI34-8.
94. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-65.
95. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85: 437-45
96. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001; 103: 750-5.
97. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104: 2407-11.
98. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy. A pharmaceutical perspective. J Control Release 2006; 113: 189-207
99. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J Nutr 2000; 130: 2343-8
100. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinone in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun 1990; 169: 851-7.
101. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q 10. Clin Investig 1993; 71: S116-23.
102. Belardinelli R, Mucaj A, Lacalaprice F, Solenghi M, Seddaiu G, Principi F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006; 27: 2675-81.
103. Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev 2007; 65: 286-93.
104. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50.
105. Review: Alternative Medicine Review Monograph: Coenzyme Q10 2007; 12: 159-68.
106. Jackson G. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis. Int J Clin Pract 2006; 60: 891-2.
107. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 24; 116: 434-48.
108. Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 2007; 13(21): 2208-13.
109. Bolignano D, Coppolino G, Criseo M, Campo S, Romeo A, Buemi M. Aquaretic agents: what's beyond the treatment of hyponatremia? Curr Pharm Des 2007; 13(8): 865-71.
110. De Luca L, Fonarow GC, Mebazaa A, Shin DD, Collins SP, Swedberg K, et al. Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials. Acute Card Care 2007; 9(1): 10-21.